Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (784)	6/22/2001 1:56:19 PM
From: keithcray	Read Replies (3) \| Respond to of 208838

Check out EBAY, I should have stayed with that one.

To: 2MAR$ who wrote (784)	6/22/2001 1:59:47 PM
From: keithcray	Respond to of 208838

NTAP nearly a point off it's high.

To: 2MAR$ who wrote (784)	6/22/2001 2:09:22 PM
From: keithcray	Read Replies (2) \| Respond to of 208838

13:44 ET Biogen (BGEN) 61.56 -5.24 (-7.8%): -- Update -- Merrill Lynch expecting BGEN to present its official Amevive Phase III data at the Psoriasis meetings later this afternoon. According to firm, NY Times reporting on its site that the Amevive Phase III data is significantly worse than firm expected in terms of percentage of patients who responded to the drug and relative to Genentech data presented yesterday. Based on NY Times numbers, results were roughly half as good as firm expected.